

Supporting Information

Transannulation of 1-Sulfonyl-1,2,3-Triazoles with Heterocumulenes

Stepan Chuprakov, Sen Wai Kwok, and Valery V. Fokin*

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

E-mail: fokin@scripps.edu

Content

General Information	S2
Starting Materials	S3
Optimization	S5
Rh ₂ (S-NTTL) ₄ -Catalyzed transannulation of 1-mesyl-1,2,3-triazoles with isocyanates and isothiocyanates	S7
Desulfonylation of N-mesyl-substituted products 2 and 3	S18
X-Ray crystallography analysis of 2a and 3a	S19
Spectral Charts	S23


General Information

^1H , ^{13}C and ^{19}F NMR spectra were recorded on a Bruker DRX-600, a Bruker DRX-500, and a Bruker AMX-400. Infrared spectra were recorded on a Nicolet Avatar 370 and on a Perkin-Elmer Spectrum 100 Fourier transform infrared spectrometers. Melting points were determined using a Thomas-Hoover melting point apparatus and are uncorrected. HPLC was performed on an Agilent 1100 LC/MSD equipped with an Agilent 1100 SL mass spectrometer (ES) eluting with 0.1% trifluoroacetic acid in H_2O and 0.05% trifluoroacetic acid in CH_3CN . Column chromatography was carried out employing EMD (Merck) Silica Gel 60 (40-63 μm). Precoated Merck F-254 silica gel plates were used for a thin layer analytical chromatography. Chloroform was purchased from Fischer (certified ACS grade containing *ca.* 0.75 % of ethanol) and distilled from phosphorous pentoxide under inert atmosphere. $\text{Rh}_2(\text{Oct})_4$, $\text{Rh}_2(\text{esp})_2$ and $\text{Rh}_2(\text{S-PTAD})_4$ were purchased from Strem Chemicals, and $\text{Rh}_2(\text{Piv})_4$,¹ $\text{Rh}_2(\text{TPA})_4$,² $\text{Rh}_2(\text{S-PTV})_4$,² $\text{Rh}_2(\text{S-PTTL})_4$,³ $\text{Rh}_2(\text{S-NTV})_4$,⁴ $\text{Rh}_2(\text{S-NTTL})_4$ ⁴ were prepared using literature procedures. Sulfonyl azides were prepared using standard methods.⁵ All isocyanates and isothiocyanates were purchased from Aldrich, Acros Organics, AK Scientific, TCI or Alfa Aesar and were re-distilled prior to use.

-
- (1) Cotton, F. A.; Felthouse, T. R. *Inorg. Chem.* **1980**, *19*, 323.
 - (2) Hashimoto, S.; Watanabe, N.; Sato, T.; Shiro, M.; Ikegami, S. *Tetrahedron Lett.* **1993**, *34*, 5109.
 - (3) Tsutsui, H.; Abe, T.; Nakamura, S.; Anada, M.; Hashimoto, S. *Chem. Pharm. Bull.* **2005**, *53*, 1366.
 - (4) (a) Müller, P.; Allenbach, Y. F.; Robert, E. *Tetrahedron: Asymmetry* **2003**, *14*, 779. (b) Müller, P.; Bernardinelli, G.; Allenbach, Y. F.; Ferry, M.; Flack, H. D. *Org. Lett.* **2004**, *6*, 1725.
 - (5) (a) Breslow, D. S.; Sloan, M. F.; Newburg, N. R.; Renfrow, W. B. *J. Am. Chem. Soc.* **1969**, *91*, 2273. (b) Danheiser, R. L.; Miller, R. F.; Brisbois, R. G.; Park, S. Z. *J. Org. Chem.* **1990**, *55*, 1959.


Starting Materials

N-Sulfonyl 1,2,3-triazoles **1** were prepared using the reported CuTC-catalyzed azide-alkyne cycloaddition (CuAAC) protocol.⁶ However, due to the potential danger of methanesulfonyl azide, we strongly recommend to avoid isolating this compound in large quantities. Generation of mesyl azide, followed by immediate use is highly preferred. 1-Sulfonyl-1,2,3-triazoles **1**, as previously reported,^{6b} may gradually hydrolyze if atmospheric moisture is not excluded; therefore, a glove box was used for prolonged storage and manipulating the triazoles. Compounds **1a-b**,^{6b} **1e-f**,^{6b} **1g**,^{3c} **1h**,^{6b} and **1j-k**^{6b} were previously reported.




- (6) (a) Raushel, J.; Fokin, V. V. *Org. Lett.* **2010**, *12*, 4952. (b) Chuprakov, S.; Kwok, S. W.; Zhang, L.; Lercher, L.; Fokin, V. V. *J. Am. Chem. Soc.* **2009**, *131*, 18034. (c) Chuprakov, S.; Malik, J. A.; Zibinsky, M.; Fokin, V. V. *J. Am. Chem. Soc.* **2011**, *133*, 10352.

4-(3-Fluorophenyl)-1-(methylsulfonyl)-1H-1,2,3-triazole (**1c**)




1c: ^1H NMR (500 MHz, CDCl_3) δ ppm 8.33 (s, 1H), 7.65–7.56 (m, 2H), 7.48–7.38 (m, 1H), 7.15–7.05 (m, 1H), 3.58 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 163.1 (d, $J = 246.7$ Hz), 146.3 (d, $J = 2.6$ Hz), 130.8 (d, $J = 8.3$ Hz), 130.7 (d, $J = 8.6$ Hz), 121.8 (d, $J = 2.9$ Hz), 119.4, 116.2 (d, $J = 21.2$ Hz), 113.2 (d, $J = 23.3$ Hz), 42.7; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -112.1; FT IR: 1588, 1474, 1453, 1353, 1339, 1202, 1183, 1156, 1005, 950, 876, 855, 783, 766 cm^{-1} ; mp 129–132 $^\circ\text{C}$; LRMS (ESI) m/z 242.2 $[\text{M} + \text{H}]^+$.

1-(Methylsulfonyl)-4-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (**1d**)



1d: ^1H NMR (500 MHz, CDCl_3) δ ppm 8.40 (s, 1H), 8.12 (s, 1H), 8.09–8.02 (m, 1H), 7.69–7.64 (m, 1H), 7.63–7.57 (m, 1H), 3.60 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 146.1, 131.6 (q, $J = 32.6$ Hz), 129.7, 129.5, 129.3, 125.9 (q, $J = 3.7$ Hz), 123.8 (q, $J = 272.4$ Hz), 123.0 (q, $J = 3.8$ Hz), 119.5, 42.7; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -63.1; FT IR: 1379, 1358, 1299, 1200, 1180, 1163, 1125, 1068, 999, 949, 800, 772 703, 695 cm^{-1} ; mp 107–109 $^\circ\text{C}$; LRMS (ESI-TOF) m/z 292.2 $[\text{M} + \text{H}]^+$.

4-(2-Methoxyphenyl)-1-(methylsulfonyl)-1H-1,2,3-triazole (**1i**)



1i: ^1H NMR (500 MHz, CDCl_3) δ ppm 8.56 (s, 1H), 8.36 (dd, $J = 7.71, 1.49$ Hz, 1H), 7.43–7.34 (m, 1H), 7.13–7.08 (m, 1H), 7.01 (d, $J = 1.19$ Hz, 1H), 3.97 (s, 3H), 3.54 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 156.0, 142.9, 130.1, 128.0, 122.0, 121.0, 117.4, 110.8, 55.5, 42.7; FT IR: 1372, 1326, 1175, 1128, 1023, 995, 969, 944, 770, 757 cm^{-1} ; mp 93–94 $^\circ\text{C}$ (dec.); LRMS (ESI) m/z 254.2 $[\text{M} + \text{H}]^+$.

Optimization

Experimental procedure. To an oven-dried 0.5-2 mL micro-wave vial equipped with a stirring bar were added 0.2 mmol of 1-sulfonyl-4-phenyl-1H-1,2,3-triazole **1** and 0.002 mmol of Rh(II) carboxylate (Figure 1) under inert atmosphere (glove box). The vial was sealed, and 0.026 mL (0.24 mmol) of phenyl isocyanate was added to the vial *via* syringe, followed by 1.0 mL of anhydrous chloroform. The resulting reaction mixture was stirred at temperatures listed in Table 1, and then was analyzed by LCMS and NMR after periods of time shown in Table 1. Conversion and yield were calculated based on ^1H NMR integration using dibromomethane as an internal standard. Obtained results are summarized in Table 1.





Figure 1. Rh(II) carboxylates used in this study.

Table 1. Conditions screening for transannulation with isocyanates.


R	catalyst^a	T, °C	time, h	yield, %	conversion, %
Ts	Rh ₂ (Oct) ₄	70	0.5	<5	100
Ts	Rh ₂ (Piv) ₄	70	0.5	35	100
Ts	Rh ₂ (esp) ₂	70	0.5	33	100
Ts	Rh ₂ (S-PTV) ₄	70	0.5	56	100
Ts	Rh ₂ (S-PTTL) ₄	70	0.5	40	100
Ts	Rh ₂ (S-NTTL) ₄	rt	24	14	25
Ts	Rh ₂ (S-NTV) ₄	rt	24	59	100
Ts	Rh ₂ (S-PTTL) ₄	rt	24	51	58
Ts	Rh ₂ (S-PTAD) ₄	rt	24	58	76
Ts	Rh ₂ (S-PTV) ₄	rt	24	55	85
Ts	Rh ₂ (S-DOSP) ₄	rt	24	10	20
Ms	Rh ₂ (Piv) ₄	rt	3	53	NA
Ms	Rh ₂ (esp) ₂	rt	4	65	100
Ms	Rh ₂ (S-PTTL) ₄	rt	3	89	95
Ms	Rh ₂ (S-PTV) ₄	rt	4	56	91
Ms	Rh ₂ (S-NTV) ₄	rt	3	86	100
Ms	Rh ₂ (S-NTTL) ₄	rt	3	95	100
Ms	Rh ₂ (TPA) ₄	rt	4	10	19

^a Oct – *n*-octanoate; Piv – pivalate; Rh₂(esp)₂ – Bis[rhodium($\alpha,\alpha,\alpha',\alpha'$ -tetramethyl-1,3-benzenedipropionic acid)]; TPA – triphenylacetate.


Rh₂(S-NTTL)₄-Catalyzed transannulation of 1-mesyl-1,2,3-triazoles with isocyanates and isothiocyanates

Typical preparative procedure. To an oven-dried 2-5 mL micro-wave vial equipped with a stirring bar were added 0.223 g (1.0 mmol) of 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole **1b** and 0.0072 g (0.005 mmol) of Rh₂(S-NTTL)₄ **9** under inert atmosphere (glove box). The vial was sealed, and phenyl isocyanate (0.130 mL, 1.2 mmol) was added to the vial *via* syringe, followed by 5.0 mL of anhydrous chloroform. The resulting green reaction mixture was stirred at ambient temperature for 2 hrs until judged complete by LC and TLC analysis. Column chromatography was directly applied to the reaction mixture using silica gel (ethyl acetate-hexanes 1:2) to afford 0.297 g (0.95 mmol, 95% yield) of 1-(methylsulfonyl)-3,4-diphenyl-1H-imidazol-2(3H)-one **2b** as white solid.


1-(Methylsulfonyl)-3,4-diphenyl-1H-imidazol-2(3H)-one (2b)

 **2b**: (95% yield); ¹H NMR (500 MHz, CDCl₃) δ ppm 7.42–7.24 (m, 6H), 7.24–7.18 (m, 2H), 7.11–7.05 (m, 2H), 6.91 (s, 1H), 3.55 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ ppm 150.0, 133.9, 129.1, 128.7, 128.6, 128.0, 127.7, 127.6, 127.0, 126.6, 105.3, 40.9; FT IR: 1717, 1495, 1449, 1360, 1170, 971 cm⁻¹; mp 195–198 °C (dec.); LRMS (ESI) *m/z* 314.4 [M + H]⁺.

3-(4-Chlorophenyl)-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2c)


 **2c**: (94% yield); ¹H NMR (500 MHz, CDCl₃) δ ppm 7.38–7.26 (m, 5H), 7.17–7.13 (m, 2H), 7.11–7.06 (m, 2H), 6.90 (s, 1H), 3.54 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ ppm 149.9, 133.8, 132.4, 129.3, 129.0, 128.8, 128.2, 127.6, 127.4, 126.3, 105.6, 40.9; FT IR : 1720, 1497, 1361, 1320, 1172, 1089, 972, 719 cm⁻¹; mp 215–216 °C ; LRMS (ESI) *m/z* 349.2 [M + H]⁺.

3-(4-Methoxyphenyl)-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2d)




2d: (94% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.33–7.24 (m, 3H), 7.17–7.05 (m, 4H), 6.92–6.86 (m, 3H), 3.82 (s, 3H), 3.54 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ ppm 159.1, 150.2, 128.7, 128.6, 128.4, 127.7, 127.6, 126.8, 126.6, 114.4, 104.9, 55.4, 40.9; FT IR: 1714, 1519, 1363, 1299, 1259, 1175, 1165, 1105, 1028, 971, 767, 715 cm^{-1} ; mp 198–200 $^\circ\text{C}$; LRMS (ESI) m/z 345.3 $[\text{M} + \text{H}]^+$.

3-(4-Bromophenyl)-4-(3-fluorophenyl)-1-(methylsulfonyl)-1H-imidazol-2(3H)-one (2e)




2e: (94% yield); ^1H NMR ($\text{DMSO}-d_6$, 500MHz) δ ppm 7.70–7.60 (m, 2H), 7.38–7.30 (m, 2H), 7.24–7.19 (m, 2H), 7.15 (dt, $J = 8.46, 2.01$ Hz, 1H), 7.09–7.00 (m, 1H), 6.96–6.86 (m, 1H), 3.63 (s, 3H); ^{13}C NMR ($\text{DMSO}-d_6$, 126MHz) δ ppm 161.7 (d, $J = 243.9$ Hz), 149.1, 133.2, 132.0, 130.5 (d, $J = 8.6$ Hz), 129.6 (d, $J = 8.9$ Hz), 129.5, 124.0 (d, $J = 2.2$ Hz), 123.5 (d, $J = 2.5$ Hz), 121.0, 115.2 (d, $J = 21.0$ Hz), 114.3 (d, $J = 23.4$ Hz), 107.2, 40.5; ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ ppm -112.0; FT IR: 1719, 1488, 1447, 1377, 1348, 1161, 1070, 970, 888, 767, 732 cm^{-1} ; mp 166–167 $^\circ\text{C}$; LRMS (ESI) m/z 411.1, 413.1 $[\text{M} + \text{H}]^+$.

3-(4-Chlorophenyl)-1-(methylsulfonyl)-4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2(3H)-one (2f)




2f: (80% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.61–7.54 (m, 2H), 7.41–7.35 (m, 2H), 7.23–7.18 (m, 2H), 7.17–7.12 (m, 2H), 7.00 (s, 1H), 3.56 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 149.7, 134.2, 132.0, 130.9, 130.8 (q, $J = 32.8$ Hz), 129.6, 128.1, 127.6, 125.8 (q, $J = 3.7$ Hz), 124.8, 123.6 (q, $J = 272.0$ Hz), 107.0, 41.0; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -63.1; mp 225–226 $^\circ\text{C}$; LRMS (ESI) m/z 417.2 $[\text{M} + \text{H}]^+$.

3-(4-Chlorophenyl)-4-(4-methoxyphenyl)-1-(methylsulfonyl)-1H-imidazol-2(3H)-one (2g)




2g: (85% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.35–7.29 (m, 2H), 7.14–7.08 (m, 2H), 7.01–6.94 (m, 2H), 6.83–6.76 (m, 3H), 3.78 (s, 3H), 3.51 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 160.0, 149.8, 133.7, 132.4, 129.3, 129.1, 128.2, 126.2, 119.6, 114.2, 104.6, 55.3, 40.9; FT IR: 1719, 1511, 1494, 1364, 1249, 1176, 1165, 1090, 974, 943, 831, 736 cm^{-1} ; mp 201 $^\circ\text{C}$ (dec.); LRMS (ESI) m/z 379.2 $[\text{M} + \text{H}]^+$.

1-(Methylsulfonyl)-4-phenyl-3-(4-(trifluoromethyl)phenyl)-1H-imidazol-2(3H)-one (2h)




2h: (83% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.64–7.58 (m, 2H), 7.35–7.27 (m, 5H), 7.08–7.04 (m, 2H), 6.90 (s, 1H), 3.53 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ ppm 149.8, 137.0, 129.7 (q, $J = 32.8$ Hz), 129.1, 128.9, 127.6, 127.2, 126.9, 126.2 (q, $J = 3.7$ Hz), 126.0, 123.6 (q, $J = 272.2$ Hz), 106.1, 41.0; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -62.9; FT IR: 1719, 1361, 1335, 1156, 1115, 1071, 971, 766 cm^{-1} ; mp 186–188 $^\circ\text{C}$; LRMS (ESI) m/z 383.2 $[\text{M} + \text{H}]^+$.

1-(Methylsulfonyl)-3-(4-nitrophenyl)-4-phenyl-1H-imidazol-2(3H)-one (2i)




2i: (53% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 8.27–8.17 (m, 2H), 7.42–7.30 (m, 5H), 7.13–7.05 (m, 2H), 6.94 (s, 1H), 3.56 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ ppm 149.5, 146.3, 139.4, 129.3, 129.0, 127.6, 127.0, 125.7, 124.3, 106.7, 41.0; FT IR: 1723, 1518, 1319, 1170, 1108, 1064, 973, 943, 855, 719 cm^{-1} ; mp 223–224 $^\circ\text{C}$; LRMS (ESI) m/z 360.2 $[\text{M} + \text{H}]^+$.

3-(3-Fluorophenyl)-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2j)



2j: (89% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.38–7.26 (m, 4H), 7.12–7.08 (m, 2H), 7.08–7.02 (m, 1H), 7.02–6.96 (m, 2H), 6.91 (s, 1H), 3.55 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ ppm 162.5 (d, $J = 248.2$ Hz), 149.8, 135.1 (d, $J = 10.2$ Hz), 130.2 (d, $J = 8.9$ Hz), 129.0, 128.8, 127.5, 127.3, 126.3, 122.7 (d, $J = 3.1$ Hz), 115.1 (d, $J = 21.0$ Hz), 114.5 (d, $J = 24.3$ Hz), 105.7, 40.9; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -111.0; FT IR: 1718, 1596, 1492, 1447, 1386, 1358, 1269, 1173, 1160, 1097, 986, 870 cm^{-1} ; mp 173–175 $^\circ\text{C}$; LRMS (ESI) m/z 333.2 $[\text{M} + \text{H}]^+$.


4-(3-fluorophenyl)-1-(methylsulfonyl)-3-phenyl-1H-imidazol-2(3H)-one (2k)



2k: (92% yield); ^1H NMR (500MHz, CDCl_3) δ ppm 7.44–7.34 (m, 3H), 7.27–7.19 (m, 3H), 7.01 (dt, $J = 8.40, 2.54$ Hz, 1H), 6.95 (s, 1H), 6.89–6.85 (m, 1H), 6.81–6.77 (m, 1H), 3.55 (s, 3H); ^{13}C NMR (CDCl_3 , 126MHz) δ ppm 162.5 (d, $J = 247.2$ Hz), 149.9, 133.6, 130.3 (d, $J = 8.4$ Hz), 129.7 (d, $J = 8.5$ Hz), 129.3, 128.3, 127.0, 125.4 (d, $J = 2.6$ Hz), 123.2 (d, $J = 2.9$

Hz), 115.7 (d, $J = 21.1$ Hz), 114.5 (d, $J = 23.5$ Hz), 106.0, 40.9; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -111.9; FT IR: 1718, 1448, 1358, 1169, 1154, 986, 973, 873 720 cm^{-1} ; mp 179–180 $^\circ\text{C}$; LRMS (ESI) m/z 333.2 $[\text{M} + \text{H}]^+$.


4-(6-Methoxynaphthalen-2-yl)-1-(methylsulfonyl)-3-(4-(trifluoromethyl)phenyl)-1H-imidazol-2(3H)-one (2l)



2l: (69% yield); ^1H NMR (400MHz, CDCl_3) δ ppm 7.66–7.54 (m, 5H), 7.39–7.31 (m, 2H), 7.17 (dd, $J = 8.91, 2.53$ Hz, 1H), 7.08 (d, $J = 2.30$ Hz, 1H), 7.00–6.94 (m, 2H), 3.91 (s, 3H), 3.55 (s, 3H); ^{13}C NMR (CDCl_3 , 125MHz) δ ppm 158.6, 149.8, 137.1, 134.4, 129.7 (q, $J = 32.8$ Hz), 129.5, 128.4, 127.4, 126.9, 126.3, 126.2 (q, $J = 3.6$ Hz), 125.2, 123.6 (q, $J = 272.4$ Hz), 122.3, 119.9, 105.9, 105.7, 55.4, 41.0;


^{19}F NMR (376 MHz, CDCl_3) δ ppm -62.9; FT IR: 1723, 1365, 1320, 1274, 1214, 1158, 1110, 1068, 965, 854, 764 cm^{-1} ; mp 178–181 $^\circ\text{C}$; LRMS (ESI) m/z 463.2 $[\text{M} + \text{H}]^+$.

3-(3-Fluorophenyl)-1-(methylsulfonyl)-4-(*p*-tolyl)-1H-imidazol-2(3H)-one (2m)




2m: (85% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.36–7.30 (m, 1H), 7.13–7.08 (m, 2H), 7.08–7.02 (m, 1H), 7.01–6.94 (m, 4H), 6.86 (s, 1H), 3.54 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 162.5 (d, $J = 248.0$ Hz), 149.8, 139.1, 135.2 (d, $J = 10.0$ Hz), 130.2 (d, $J = 9.0$ Hz), 129.5, 127.5, 126.4, 124.3, 122.8 (d, $J = 3.3$ Hz), 115.1 (d, $J = 21.1$ Hz), 114.6 (d, $J = 24.2$ Hz), 105.2, 40.9, 21.2; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -111.1; FT IR: 1718, 1595, 1491, 1359, 1268, 1160, 1173, 986, 867, 767 cm^{-1} ; mp 203–205 $^\circ\text{C}$; LRMS (ESI) m/z 347.2 $[\text{M} + \text{H}]^+$.

3-Butyl-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2n)




2n: (97% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.48–7.41 (m, 3H), 7.36–7.31 (m, 2H), 6.64 (s, 1H), 3.70–3.59 (m, 2H), 3.47 (s, 3H), 1.53–1.43 (m, 2H), 1.25–1.13 (m, 2H), 0.79 (t, $J = 7.37$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ ppm 150.7, 129.4, 129.0, 128.5, 128.1, 127.0, 104.3, 41.8, 40.7, 30.8, 19.6, 13.4; FT IR: 1710, 1451, 1357, 1171, 1133, 1060, 967, 762 cm^{-1} ; mp 54–56 $^\circ\text{C}$; LRMS (ESI) m/z 295.4 $[\text{M} + \text{H}]^+$.

3-Allyl-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2o)




2o: (85% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.46–7.40 (m, 3H), 7.38–7.33 (m, 2H), 6.69 (s, 1H), 5.81 (ddt, $J = 17.06, 10.33, 5.17$ Hz, 1H), 5.18 (d, $J = 10.33$ Hz, 1H), 5.05 (d, $J = 17.12$ Hz, 1H), 4.25 (td, $J = 5.11, 1.51$ Hz, 2H), 3.48 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 150.6, 132.0, 129.4, 128.9, 128.5, 127.7, 127.2, 117.7, 104.4, 44.3, 40.8; FT IR: 1705, 1449, 1347, 1325, 1166, 1150, 1099, 998, 967 cm^{-1} ; mp 87–91 $^\circ\text{C}$; LRMS (ESI) m/z 279.2 $[\text{M} + \text{H}]^+$.

3-Cyclohexyl-1-(methylsulfonyl)-4-phenyl-1H-imidazol-2(3H)-one (2p)




2p: (95% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.48–7.41 (m, 3H), 7.32–7.27 (m, 2H), 6.58 (s, 1H), 3.58 (tt, $J = 12.16, 3.83$ Hz, 1H), 3.47 (s, 3H), 2.34–2.21 (m, 2H), 1.84–1.67 (m, 4H), 1.62–1.52 (m, 1H), 1.21–1.06 (m, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 150.0, 129.3, 129.1, 128.9, 128.3, 127.2, 104.4, 55.3, 40.7, 29.6, 25.8, 24.8; FT IR: 1711, 1372, 1358, 1173, 1125, 966, 769, 758 cm^{-1} ; mp 123–126 $^\circ\text{C}$; LRMS (ESI) m/z 321.2 $[\text{M} + \text{H}]^+$.

3-Benzyl-1-(methylsulfonyl)-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2(3H)-one (2q)




2q: (93% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.71–7.65 (m, 1H), 7.52 (t, $J = 7.77$ Hz, 1H), 7.44 (s, 1H), 7.42–7.38 (m, 1H), 7.31–7.25 (m, 3H), 7.09–7.03 (m, 2H), 6.78 (s, 1H), 4.84 (s, 2H), 3.55 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 151.0, 135.9, 132.0, 131.3 (q, $J = 32.9$ Hz), 129.5, 128.8, 128.6, 128.0, 127.2, 126.1 (q, $J = 3.7$ Hz), 125.8, 125.7 (q, $J = 3.8$ Hz), 123.4 (q, $J = 272.6$ Hz), 105.5, 45.8, 40.9; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -63.2; FT IR: 1724, 1354, 1327, 1283, 1165, 1093, 1073, 974, 761, 725 cm^{-1} ; mp 99–101 $^\circ\text{C}$; LRMS (ESI) m/z 397.2 $[\text{M} + \text{H}]^+$.

3-(3-Chloropropyl)-1-(methylsulfonyl)-4-(p-tolyl)-1H-imidazol-2(3H)-one (2r)




2r: (90% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.31–7.22 (m, 4H), 6.65 (s, 1H), 3.86–3.81 (m, 2H), 3.51–3.46 (m, 5H), 2.43 (s, 3H), 2.06 (qd, $J = 12.92, 6.37$ Hz, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 150.7, 139.8, 129.8, 128.5, 126.9, 124.5, 104.3, 41.8, 40.8, 39.8, 31.4, 21.3; FT IR: 1706, 1382, 1354, 1297, 1170, 1147, 1097, 1009, 977, 824, 772, 723 cm^{-1} ; mp 142–143 $^\circ\text{C}$; LRMS (ESI) m/z 329.2 $[\text{M} + \text{H}]^+$.

3-(2-Bromoethyl)-4-(4-methoxyphenyl)-1-(methylsulfonyl)-1H-imidazol-2(3H)-one (2s)




2s: (92% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.33–7.26 (m, 2H), 7.04–6.96 (m, 2H), 6.63 (s, 1H), 4.03 (t, $J = 6.89$ Hz, 2H), 3.88 (s, 3H), 3.49 (s, 3H), 3.46 (t, $J = 6.90$ Hz, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 160.6, 150.5, 130.3, 126.4, 119.4, 114.6, 104.5, 55.4, 43.0, 40.1, 27.8; FT IR: 1712, 1348, 1256, 1212, 1161, 1081, 834, 767, 733 cm^{-1} ; mp 128–130 $^\circ\text{C}$; LRMS (ESI) m/z 375.1, 377.1 $[\text{M} + \text{H}]^+$.

(Z)-N-(3-(Methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)aniline (3a)




3a: (87% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.43–7.28 (m, 8H), 7.20–7.14 (m, 1H), 7.13–7.07 (m, 2H), 3.66 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 152.8, 149.6, 130.3, 129.6, 129.0, 128.5, 125.2, 124.8, 120.8, 117.8, 116.6, 41.0; FT IR: 1621, 1587, 1364, 1354, 1162, 1119, 958, 829, 748 cm^{-1} ; mp 102–104 $^\circ\text{C}$; LRMS (ESI) m/z 331.2 $[\text{M} + \text{H}]^+$.

(Z)-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)benzamide (3b)




3b: (91% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 8.37–8.28 (m, 2H), 7.67 (s, 1H), 7.59–7.54 (m, 1H), 7.53–7.46 (m, 4H), 7.46–7.36 (m, 3H), 3.80 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 174.3, 165.9, 135.4, 132.7, 129.9, 129.7, 129.3, 129.1, 128.4, 125.9, 125.2, 115.6, 41.6; FT IR: 1609, 1573, 1464, 1368, 1328, 1231, 1175, 1152, 971, 881, 751 cm^{-1} ; mp 163 $^\circ\text{C}$ (dec.); LRMS (ESI) m/z 359.2 $[\text{M} + \text{H}]^+$.

(Z)-4-chloro-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)aniline (3c)




3c: (51% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.39–7.28 (m, 8H), 7.06–7.01 (m, 2H), 3.64 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 153.9, 148.5, 130.6, 130.4, 130.1, 129.5, 129.1, 125.7, 122.7, 118.4, 117.2, 41.5; mp 144–145 °C; LRMS (ESI) m/z 365.3 $[\text{M} + \text{H}]^+$.

(Z)-2-bromo-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)aniline (3d)




3d: (95% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.68 (dd, $J = 8.02, 1.28$ Hz, 1H), 7.40 (s, 1H), 7.40–7.30 (m, 6H), 7.20 (dd, $J = 7.90, 1.49$ Hz, 1H), 7.06 (dt, $J = 7.94, 1.55$ Hz, 1H), 3.81 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 154.4, 148.1, 133.3, 130.1, 129.0, 128.7, 128.6, 126.0, 125.2, 121.0, 118.1, 117.1, 117.0, 41.3; FT IR: 1620, 1574, 1469, 1364, 1162, 1117, 1028, 973, 961, 827, 745 cm^{-1} ; mp 145–146 °C; LRMS (ESI) m/z 409.2, 411.2 $[\text{M} + \text{H}]^+$.

(Z)-4-chloro-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)benzamide (3e)




3e: (82% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 8.26–8.22 (m, 2H), 7.67 (s, 1H), 7.52–7.48 (m, 2H), 7.47–7.37 (m, 5H), 3.78 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 173.3, 166.2, 139.0, 134.0, 131.0, 129.8, 129.3, 129.2, 128.7, 125.9, 125.4, 115.7, 41.7; FT IR: 1606, 1591, 1490, 1471, 1333, 1230, 1175, 1143, 960, 879 754 cm^{-1} ; mp 180 °C (dec.); LRMS (ESI) m/z 393.2 $[\text{M} + \text{H}]^+$.

(Z)-2-chloro-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)ethanamine (3f)




3f: (59% yield, 35% of triazole recovered); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.40–7.30 (m, 5H), 7.29 (s, 1H), 3.84 (t, $J = 5.94$ Hz, 2H), 3.57–3.53 (m, 5H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 153.1, 130.4, 129.0, 128.4, 125.1, 117.7, 117.0, 56.8, 44.5, 40.7; mp 100–102 °C; LRMS (ESI) m/z 317.1 $[\text{M} + \text{H}]^+$.

(Z)-4-methoxy-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)aniline (3g)




3g: (48% yield, 49% of triazole recovered); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.39–7.27 (m, 6H), 7.07–7.02 (m, 2H), 6.96–6.91 (m, 2H), 3.82 (s, 3H), 3.64 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 156.7, 152.1, 142.8, 130.4, 129.0, 128.4, 125.2, 121.9, 117.7, 116.6, 114.7, 55.4, 41.0; FT IR: 1624, 1593, 1501, 1356, 1239, 1159, 1116, 956, 821, 748 cm^{-1} ; mp 129–130 °C; LRMS (ESI) m/z 361.2 $[\text{M} + \text{H}]^+$.

(Z)-N-(3-(methylsulfonyl)-5-phenylthiazol-2(3H)-ylidene)-3,5-bis(trifluoromethyl)aniline (3h)




3h: (96% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.66 (s, 1H), 7.56 (s, 2H), 7.41–7.30 (m, 6H), 3.67 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 155.5, 150.6, 133.0 (q, $J = 33.4$ Hz), 129.6, 129.3, 128.9, 125.4, 123.1 (q, $J = 272.8$ Hz), 121.6, 118.2, 118.0 (septet, $J = 3.8$ Hz), 117.0, 41.2; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -63.2; FT IR: 1628, 1590, 1378, 1361, 1268, 1167, 1120, 949, 890, 749 cm^{-1} ; mp 145–146 °C; LRMS (ESI) m/z 467.1 $[\text{M} + \text{H}]^+$.

(Z)-N-(5-(2-Methoxyphenyl)-3-(methylsulfonyl)thiazol-2(3H)-ylidene)aniline (3i)




3i: (70% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.70 (s, 1H), 7.45–7.39 (m, 2H), 7.32–7.26 (m, 1H), 7.21–7.11 (m, 4H), 6.99–6.92 (m, 2H), 3.93 (s, 3H), 3.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 156.3, 152.9, 149.7, 129.5, 129.1, 128.0, 124.5, 120.9, 120.9, 120.1, 119.1, 114.0, 111.1, 55.5, 40.9; FT IR: 1621, 1583, 1493, 1359, 1301, 1251, 1173, 1130, 1116, 1016, 972, 833, 753 cm^{-1} ; mp 120–121 $^\circ\text{C}$; LRMS (ESI) m/z 361.2 $[\text{M} + \text{H}]^+$.

(Z)-N-(5-(cyclohex-1-en-1-yl)-3-(methylsulfonyl)thiazol-2(3H)-ylidene)benzamide (3j)




3j: (45% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 8.34–8.24 (m, 2H), 7.58–7.51 (m, 1H), 7.51–7.45 (m, 2H), 7.23 (s, 1H), 6.07 (t, $J = 3.84$ Hz, 1H), 3.74 (s, 3H), 2.32–2.18 (m, 4H), 1.80–1.62 (m, 4H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 174.2, 165.6, 135.6, 132.6, 129.6, 128.5, 128.4, 127.8, 127.0, 114.0, 41.6, 26.0, 25.7, 22.1, 21.8; mp 168 $^\circ\text{C}$ (dec.); LRMS (ESI) m/z 363.2 $[\text{M} + \text{H}]^+$.

(Z)-2-bromo-N-(5-(4-methoxyphenyl)-3-(methylsulfonyl)thiazol-2(3H)-ylidene)aniline (3k)




3k: (97% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.66 (dd, $J = 8.01$, 1.27 Hz, 1H), 7.36 (dt, $J = 7.72$, 1.32 Hz, 1H), 7.27–7.23 (m, 3H), 7.19 (dd, $J = 7.90$, 1.49 Hz, 1H), 7.05 (dt, $J = 7.82$, 1.52 Hz, 1H), 6.91–6.88 (m, 2H), 3.83 (s, 3H), 3.79 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 159.9, 154.6, 148.2, 133.3, 128.7, 126.7, 125.9, 122.6, 121.1, 118.0, 117.1, 115.6, 114.5, 55.4, 41.2; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -63.2; FT IR: 1627, 1608, 1576, 1509, 1461, 1359, 1289, 1249, 1163, 1127, 1117, 1030, 972, 962, 816, 824 cm^{-1} ; mp 131–132 $^\circ\text{C}$; LRMS (ESI) m/z 439.1, 441.0 $[\text{M} + \text{H}]^+$.

(Z)-N-(3-(methylsulfonyl)-5-(thiophen-3-yl)thiazol-2(3H)-ylidene)aniline (3l)




3l: (64% yield); ¹H NMR (500 MHz, CDCl₃) δ ppm 7.45–7.39 (m, 2H), 7.37 (dd, *J* = 5.02, 2.91 Hz, 1H), 7.27 (s, 1H), 7.22–7.17 (m, 1H), 7.16 (dd, *J* = 5.03, 0.85 Hz, 1H), 7.13–7.09 (m, 3H), 3.66 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ ppm 152.5, 149.6, 131.2, 129.6, 127.2, 124.8, 124.4, 121.2, 120.8, 116.6, 113.4, 40.9; FT IR: 1634, 1610, 1582, 1353, 1162, 1119, 955, 754, 698 cm⁻¹; mp 118–119 °C; LRMS (ESI) *m/z* 337.1 [M + H]⁺.

(Z)-N-(3-(methylsulfonyl)-5-(thiophen-3-yl)thiazol-2(3H)-ylidene)-3,5-bis(trifluoromethyl)aniline (3m)




3m: (92% yield); ¹H NMR (500 MHz, CDCl₃) δ ppm 7.65 (s, 1H), 7.54 (s, 2H), 7.38 (dd, *J* = 5.08, 2.94 Hz, 1H), 7.29 (s, 1H), 7.16 (dd, *J* = 2.90, 1.21 Hz, 1H), 7.14 (dd, *J* = 5.06, 1.35 Hz, 1H), 3.65 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ ppm 155.2, 150.6, 133.0 (q, *J* = 33.3 Hz), 130.5, 127.5, 124.5, 123.1 (q, *J* = 273.0 Hz), 121.9, 121.5, 118.1 (q, *J* = 3.7 Hz), 116.9, 113.7, 41.2; ¹⁹F NMR (376 MHz, CDCl₃) δ ppm -63.2; FT IR: 1630, 1596, 1379, 1360, 1277, 1264, 1166, 1118, 962, 951 cm⁻¹; mp 156–157 °C; LRMS (ESI) *m/z* 473.0 [M + H]⁺.

(Z)-N-(3-(Methylsulfonyl)-5-(*p*-tolyl)thiazol-2(3H)-ylidene)-3,5-bis(trifluoromethyl)aniline (3n)



3n: (99% yield); ¹H NMR (500 MHz, CDCl₃) δ ppm 7.67 (s, 1H), 7.58 (s, 2H), 7.37 (s, 1H), 7.26–7.18 (m, 4H), 3.68 (s, 3H), 2.38 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ ppm 155.6, 150.7, 139.1, 133.0 (q, *J* = 33.36 Hz), 129.8, 126.8, 125.3, 123.1 (q, *J* = 272.84 Hz), 121.6 (q, *J* = 2.74 Hz), 118.3, 118.0 (septet, *J* = 3.43 Hz), 116.3, 41.2, 21.2; ¹⁹F NMR (376 MHz, CDCl₃) δ ppm -63.2; mp 152–153 °C; LRMS (ESI) *m/z* 481.1 [M + H]⁺.

(Z)-N-(5-(6-methoxynaphthalen-2-yl)-3-(methylsulfonyl)thiazol-2(3H)-ylidene)aniline (3o)



3o: (50% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 7.72 (d, $J = 8.62$ Hz, 1H), 7.67 (d, $J = 8.96$ Hz, 1H), 7.56 (s, 1H), 7.50–7.41 (m, 4H), 7.24–7.11 (m, 5H), 3.94 (s, 3H), 3.69 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 158.3, 152.8, 149.7, 134.3, 129.6, 129.4, 128.6, 127.6, 125.4, 124.8, 124.4, 122.9, 120.9, 119.7, 118.2, 116.3, 105.9, 55.3, 41.0; mp 147–148 °C; LRMS (ESI) m/z 411.1 $[\text{M} + \text{H}]^+$.

Desulfonylation of N-mesyl-substituted products **2** and **3**


Method A.⁷ A mixture of 0.094g (0.3 mmol) of 1-(methylsulfonyl)-3,4-diphenyl-1H-imidazol-2(3H)-one **2b** and 0.037g (1.5 mmol) of Mg (turnings) in 5 mL of methanol was heated to 65-70 °C in a sealed vial for 12 h, until the reaction was judged complete by LCMS and TLC analysis. The reaction mixture was poured into 5 mL of 1N HCl and extracted with DCM (2x50 mL). Organic layer were washed with NaHCO_3 (saturated solution) and brine, dried over Na_2SO_4 . After removal of solvents the residue was purified by column chromatography on silica gel (EtOAc as an eluent) to afford 0.056 g (0.24 mmol, 79%) of 1,5-diphenyl-1H-imidazol-2(3H)-one **10** as a white solid with mp 233–235 °C (228–230 °C lit.). ^1H and ^{13}C NMR data were identical to those reported in literature.⁸

Method B. To a stirred solution of (Z)-N-(3-(methylsulfonyl)-5-(thiophen-3-yl)thiazol-2(3H)-ylidene)-3,5-bis(trifluoromethyl)aniline **3m** (0.142 g; 0.3 mmol) in a mixture of methanol (1 mL) and DCM (1 mL) HOBt (0.122g; 0.9 mmol) was added. The resulting mixture was stirred for 6h until judged complete by LCMS and TLC analysis. Column chromatography of the reaction mixture (silica gel, 20% EtOAc in hexanes) afforded 0.115g (98%) of compound **11** as a white solid.

N-(3,5-bis(trifluoromethyl)phenyl)-5-(thiophen-3-yl)thiazol-2-amine (**11**)

(7) Yoo, E. J.; Ahlquist, M.; Kim, S. H.; Bae, I.; Fokin, V.V.; Sharpless, K. B.; Chang, S. *Angew. Chem. Int. Ed.* **2007**, *46*, 1730.

(8) Lee, S. H.; Yoshida, K.; Matsushita, H.; Clapham, B.; Koch, G.; Zimmermann, J.; Janda, K. D. *J. Org. Chem.* **2004**, *69*, 8829.



11: (98% yield); ^1H NMR (500 MHz, CDCl_3) δ ppm 11.01 (s, 1H), 8.32 (s, 2H), 7.71 (s, 1H), 7.66–7.62 (m, 1H), 7.62–7.59 (m, 1H), 7.58 (s, 1H), 7.44 (dd, $J = 4.98, 1.35$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ ppm 160.7, 142.4, 135.1, 131.6, 130.8 (q, $J = 32.6$ Hz), 127.4, 125.6, 123.9, 123.2 (q, $J = 272.8$ Hz), 120.3, 116.2, 113.3; ^{19}F NMR (376 MHz, CDCl_3) δ ppm -61.5; FT IR: 2938, 1597, 1477, 1382, 1270, 1160, 1112, 998, 964, 767 cm^{-1} ; mp 179–180 $^\circ\text{C}$; LRMS (ESI) m/z 395.1 $[\text{M} + \text{H}]^+$.

X-Ray crystallography analysis of 2a and 3a




Figure 2. Crystal structure of compound **2a** (CCDC 888986).

Table 2. Crystal data and structure refinement for **2a**.

Empirical formula	$\text{C}_{23.50}\text{H}_{21}\text{N}_2\text{O}_4\text{S}$
Formula weight	427.48

Temperature	150(2) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	C2/c	
Unit cell dimensions	a = 21.68(5) Å	$\alpha = 90^\circ$.
	b = 5.975(14) Å	$\beta = 91.72(6)^\circ$.
	c = 31.44(7) Å	$\gamma = 90^\circ$.
Volume	4070(16) Å ³	
Z	8	
Density (calculated)	1.395 Mg/m ³	
Absorption coefficient	0.194 mm ⁻¹	
F(000)	1792	
Crystal size	0.45 x 0.10 x 0.05 mm ³	
Theta range for data collection	1.30 to 25.74°.	
Index ranges	-26 ≤ h ≤ 26, -7 ≤ k ≤ 7, -37 ≤ l ≤ 38	
Reflections collected	20923	
Independent reflections	3759 [R(int) = 0.0999]	
Completeness to theta = 25.00°	98.8 %	
Absorption correction	Multi-scan	
Max. and min. transmission	0.9904 and 0.9180	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	3759 / 0 / 255	
Goodness-of-fit on F ²	1.024	
Final R indices [I > 2σ(I)]	R1 = 0.0745, wR2 = 0.1753	
R indices (all data)	R1 = 0.1507, wR2 = 0.2027	
Extinction coefficient	0.0013(3)	
Largest diff. peak and hole	0.206 and -0.241 e.Å ⁻³	





Figure 3. Crystal structure of compound **3a** (CCDC 888987).

Table 3. Crystal data and structure refinement for **3a**.

Empirical formula	C ₁₆ H ₁₄ N ₂ O ₂ S ₂	
Formula weight	330.41	
Temperature	100(2) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	P2(1)/c	
Unit cell dimensions	a = 11.2840(9) Å	α = 90°
	b = 8.3762(8) Å	β = 93.5250(10)°
	c = 32.860(3) Å	γ = 90°
Volume	3099.9(5) Å ³	
Z	8	
Density (calculated)	1.416 g/cm ³	
Absorption coefficient	0.351 mm ⁻¹	

F(000)	1376
Crystal size	0.28 x 0.22 x 0.10 mm ³
Theta range for data collection	2.13 to 25.45°
Index ranges	-13<=h<=13, -8<=k<=10, -39<=l<=39
Reflections collected	24909
Independent reflections	5690 [R(int) = 0.0359]
Completeness to theta = 25.00°	99.6 %
Absorption correction	Multi-scan
Max. and min. transmission	0.9657 and 0.9081
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	5690 / 0 / 397
Goodness-of-fit on F ²	1.014
Final R indices [I>2sigma(I)]	R1 = 0.0309, wR2 = 0.0855
R indices (all data)	R1 = 0.0419, wR2 = 0.0917
Largest diff. peak and hole	0.302 and -0.328 e Å ⁻³

